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Introduction
Patients with interstitial lung disease have a wide range of 
diagnoses and prognoses, and some can live with their diag-
nosis and/or are responsive to treatments.1 For example, there 
is moderate evidence for the use of sildenafil and pulmonary 
rehabilitation to improve health-related quality of life in 
fibrotic interstitial lung disease. Health-related quality of life 
in patients with interstitial lung disease is mainly evaluated 
by the 36-item short-form questionnaire, Chronic Respira-
tory Questionnaire, or St George’s Respiratory Questionnaire 
(SGRQ ).1 New evaluation tools have also been developed 
specifically to assess health-related quality of life for intersti-
tial lung disease patients, such as the ATAQ-IPF (A Tool to 
Assess Quality of life in IPF; idiopathic pulmonary fibrosis) 
that is composed of 74 items2 and the King’s Brief Interstitial 
Lung Disease questionnaire with 15 items.3
Quality of life in interstitial lung disease patients has been 
correlated with the percent of predicted forced vital capacity 
(FVC), forced expiratory volume in the first second, lung dif-
fusion capacity for carbon monoxide (DLCO), the level of 
dyspnea, and the distance walked and oxygen saturation dur-
ing the 6-minute walk test (6MWT).4–6 Moreover, walking 
velocity, change in oxygen saturation with walking exercise, 
and percent of predicted DLCO have been associated with 
survival in idiopathic interstitial pneumonia.7,8
Recently, the COPD Assessment Test (CAT),9 which 
was originally developed to evaluate the health-related quality 
of life in patients with COPD, was also introduced to evalu-
ate patients with interstitial lung disease, and it was reported 
that there was a very strong correlation between the CAT 
score and the SGRQ total score (r = 0.93) in those subjects.10 
The CAT has only a short 8-item questionnaire for assessing 
health status, so it can be completed in about 2 minutes (See 
Appendix). The total score ranges from 0 to 40, with higher 
scores indicating a worse health status.11 However, the CAT 
has not been examined as a prognostic marker in interstitial 
lung disease; some patients with interstitial lung disease have 
a short disease trajectory and a similar prognosis to patients 
with lung cancer.1 The aim of this study was to apply this sim-
ple instrument to patients with interstitial lung disease and to 
verify the CAT as a predictor of outcome.
Methods
This study included 101 consecutive patients (53 females and 
48 males, with an average age of 63.8 years) with interstitial 
lung disease defined by high-resolution computed tomography 
(Table 1).12 They were transferred to Kanazawa University 
Hospital, Japan, between January 2013 and July 2015 for rou-
tine evaluation or treatment. All patients were evaluated by the 
CAT on the day of their first visit and followed up for more 
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than one year (median, 18 months). We performed a review of 
hospital records for the patient data. As this study was per-
formed retrospectively, written informed consent for partici-
pation in the study was not obtained from patients, and subject 
records were anonymized prior to analysis. The use of patient 
records for the study was approved by the Human Ethics 
Committee of Kanazawa University. Kanazawa University, 
conforming to the provisions of the Declaration of Helsinki.
Thirty-six patients were diagnosed with idiopathic inter-
stitial pneumonia, and the others were diagnosed with con-
nective tissue disease-associated interstitial lung diseases. The 
percent of predicted FVC and DLCO were collected from the 
pulmonary function tests.
statistical analysis. The CAT scores were categorized 
into low (CAT # 10), medium (11 # CAT # 20), high 
(21 # CAT # 30), and very high (CAT . 30) impact accord-
ing to the severity.13 Statistical analysis was performed using 
analysis of variance and Tukey’s honestly significant dif-
ference (HSD) test for multiple comparisons of values and 
the chi-squared test for comparison of frequencies classi-
fied by impacts evaluated by the CAT. Survival according to 
severity of the CAT score was illustrated via Kaplan–Meier 
curves. Cox regression analysis was used to examine mortal-
ity in terms of age, CAT score, percent of predicted FVC and 
DLCO, and home oxygen therapy. JMP 11 software (SAS 
Institute Inc.) was used for statistical analysis. P , 0.05 was 
considered significant.
results
Gender, height, weight, and time since diagnosis were not 
different among subdivided patients according to CAT scores 
(Table 1). Patients with medium impact were older than 
patients with low impact. Nine patients used home oxygen 
therapy (up to 3 L/minute). Patients with higher CAT scores 
exhibited significantly lower percentages of predicted FVC 
and DLCO than those with lower CAT scores, a difference 
that was especially pronounced between patients with low and 
medium or high impact.
During the follow-up period, 12 patients died and at least 
9 deaths from pulmonary insufficiency were put on record in 
our hospital. Mortality in patients with higher CAT scores 
was significantly higher than in patients with lower CAT 
scores (log-rank test, P = 0.0002; Fig. 1). In univariate models, 
the mortality hazard ratio of high CAT scores vs. low CAT 
scores was 5.11 (P = 0.04), and hazard ratio of very high CAT 
scores vs. low CAT scores and vs. medium CAT scores was 
19.50 and 14.38 (P = 0.01 for both), respectively. The haz-
ard ratios for FVC per 1% predicted and DLCO per 1% pre-
dicted were 0.97 and 0.94 (P = 0.02 for both; Table 2). Age 
and home oxygen therapy did not influence the hazard ratio. 
Relative hazards in multivariate models were also calculated 
for the same variables. The mortality hazard ratios of very 
high CAT scores vs. low, medium, and high CAT scores were 
13.27, 35.95, and 428.51(P = 0.04, P = 0.005, and P = 0.001), 
















gender (f/m) 53/48 23/12 19/24 10/11 1/1 ns
age (yrs) 63.8 ± 12.6 60.3 ± 15.1 68.0 ± 9.9 61.0 ± 11.2 64.0 0.04 (l vs. M)
height (cm) 159 ± 9 160 ± 10 158 ± 8 160 ± 10 163 ns
Weight (kg) 57 ± 11 57 ± 11 56 ± 10 56 ± 14 70 ns
time since diagnosis (yrs) 6.3 ± 7.2 7.4 ± 7.7 5.7 ± 5.4 6.4 ± 9.6 1.3 ns
home oxygen therapy (y/n) 9/92 0/35 3/40 6/15 0/2 na
FVC (% pred) 84.2 ± 24.6 97.6 ± 19.9 81.4 ± 23.5 66.7 ± 23.7 80.0 ,0.001 (l vs. h)
0.01 (l vs. M)
dlCo (% pred) 48.1 ± 20.0 61.6 ± 17.1 42.5 ± 16.3 35.2 ± 21.9 39.4 0.0001 (l vs. h and M)
notes: data are expressed as mean ± sd or absolute numbers. no sd is calculated in the group of Cat . 30 because the number of patients was only two.
Abbreviations: Cat, Copd assessment test; FVC, forced vital capacity; dlCo, lung diffusion capacity for carbon monoxide; l, low impact; M, medium impact;  
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figure 1. Kaplan–Meier survival curves according to severity of Cat 
score. solid line: Cat score #10; dash line: 11–20; dash and dotted line: 
21–30; dotted line: .30. survival curves were compared with the log-
rank statistic, P = 0.0002.
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respectively. The hazard ratio for DLCO per 1% predicted was 
0.88 (P = 0.003).
discussion
Our data demonstrate a relationship between higher CAT 
scores and lower pulmonary function and that higher CAT 
scores indicate a higher hazard of dying during follow-up of 
18 months. Moreover, severely deteriorated quality of life was an 
independent factor from impaired DLCO in terms of mortality. 
Previous studies have demonstrated the relationship between 
quality of life and pulmonary functions such as FVC and 
DLCO or results of the 6MWT in interstitial lung disease,3–6 
and our results supported the validity of the CAT. However, 
no study has referred to the relationship between the CAT and 
outcomes in those patients. The CAT, comprising only eight 
items and able to be completed in short time,11 appears to be 
useful as a prognostic marker for interstitial lung disease.
In this study, we found a significant independent rela-
tionship between the percent of predicted DLCO and sur-
vival, demonstrated by relative hazards in multivariate models. 
A conflicting study reported that the percent of predicted FVC 
and DLCO did not directly affect the hazard ratio for death in 
idiopathic interstitial pneumonia,8 whereas in patients with sys-
temic sclerosis, systolic pulmonary artery pressure and DLCO 
(cutoff value: 64%) were found to be independently associated 
with the risk of death.14,15 In this study, 9 of 12 deaths were of 
patients with idiopathic interstitial pneumonia, while the others 
were patients with systemic sclerosis or mixed connective tissue 
disease, who showed percent of predicted DLCO values lower 
than 64%. Therefore, it is suggested that percent of predicted 
DLCO should be considered one of the factors for predicting 
survival in widely classified interstitial lung disease.
The status of oxygen therapy in this study did not show 
a significant effect on survival, although oxygen therapy may 
be beneficial for maintaining oxygen saturation. However, 
the lack of association between home oxygen therapy and 
survival cannot be generalized because of the low number of 
subjects (nine patients). Generally, long-term oxygen therapy 
is known to improve survival without affecting quality of life 
in patients with COPD.16 Previously, deterioration in quality 
of life in interstitial lung disease compared with COPD was 
reported,17,18 and it was thought to be due to differences in 
the dyspnea mechanism or in the rate of disease progression. 
For example, forced expiratory volume in the first second was 
associated with health status in COPD,19 whereas FVC and 
DLCO also showed significant correlations with quality of 
life in interstitial lung disease.20
There were some limitations to this study. First, medica-
tions or complications were not taken into account, although 
different clinical approaches and survival rates were suggested 
depending on lung biopsy findings or underlying diseases 
associated with interstitial lung disease.21,22 Second, the study 
was retrospectively performed at a single facility. We cannot 
deny the possibility of an unexpected bias among the present 
patients, even though we analyzed consecutive patients who 
visited our facility. Further multicenter studies will be needed 
to assess longitudinal changes regarding health status.
conclusion
This work has demonstrated that it is possible to relate CAT 
scores to mortality in patients with interstitial lung disease, 
similar to lung perfusion disturbance. Considering that the 
CAT needs no special equipment to evaluate the health status 
of patients, the CAT may have a potential for use in everyday 
clinical practice regarding mortality hazard for patients with 
interstitial lung disease.
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Table 2. Cox regression analysis of survival-related parameters.
vARIAbLES unIvARIATE MuLTIvARIATE
RELATIvE hAzARD (95% CI) P RELATIvE hAzARD (95% CI) P
age 1.03 (0.99–1.09) ns 1.07 (0.98–1.22) ns
Cat categories
 Medium/low 1.36 (0.22–10.30) ns 0.37 (0.04–8.41) ns
 high/low 5.11 (1.10–35.75) 0.04 0.03 (0.00–2.28) ns
 high/Medium 3.77 (0.92–18.40) ns 0.08 (0.00–1.96) ns
 Very high/low 19.50 (2.33–162.95) 0.01 13.27 (1.20–305.53) 0.04
 Very high/Medium 14.38 (1.89–87.01) 0.01 35.95 (3.40–593.63) 0.005
 Very high/high 3.81 (0.54–17.76) ns 428.51 (9.21–130916.4) 0.001
home oxygen therapy (y/n) 2.35 (0.36–8.94) ns 15.97 (0.31–964.31) ns
FVC (% pred) 0.97 (0.94–0.996) 0.02 0.996 (0.94–1.05) ns
dlCo (% pred) 0.94 (0.87–0.99) 0.02 0.88 (0.78–0.96) 0.003
Abbreviations: CI, confidence interval; CAT, COPD Assessment Test; FVC, forced vital capacity; DLCO, lung diffusion capacity for carbon monoxide;  
NS, not significant.
Someya et al
30 CliniCal MediCine insights: CirCulatory, respiratory and pulMonary MediCine 2016:10
Participated in the design of the study and data collection: 
TN. Contributed to the conception, data acquisition, and 
approval of the manuscript: NM. All the authors reviewed 
and approved the final manuscript.
references
 1. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and 
quality of life of patients with fibrotic interstitial lung disease: a systematic review 
of the literature. Thorax. 2013;68:867–79.
 2. Swigris JJ, Wilson SR, Green KE, Sprunger DB, Brown KK, Wamboldt FS. 
Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health 
Qual Life Outcomes. 2010;8:77.
 3. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the 
King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. 
Thorax. 2012;67:804–10.
 4. Martinez TY, Pereira CAC, dos Santos ML, Ciconelli RM, Guimaraes SM, 
Martinez JAB. Evaluation of the Short-Form 36-item questionnaire to mea-
sure health-related quality of life in patients with idiopathic pulmonary fibrosis. 
Chest. 2000;117:1627–32.
 5. Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC chronic Dyspnea 
Scale: relationships with cardiopulmonary exercise testing and 6-minute walk 
test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm 
Med. 2010;10:32.
 6. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic 
pulmonary fibrosis: test validation and minimal clinically important difference. 
Am J Respir Crit Care Med. 2011;183:1231–7.
 7. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The 
timed walk test as a measure of severity and survival in idiopathic pulmonary 
fibrosis. Eur Respir J. 2005;25:96–103.
 8. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation dur-
ing a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit 
Care Med. 2003;168:1084–90.
 9. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Leidy NK. Develop-
ment and first validation of the COPD Assessment Test. Eur Respir J. 
2009;34:648–54.
 10. Nagata K, Tomii K, Otsuka K, et al. Evaluation of the chronic obstructive pul-
monary disease assessment test for measurement of health-related quality of life 
in patients with interstitial lung disease. Respirology. 2012;17:506–12.
 11. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of 
life with CAT, CCQ , and SGRQ in COPD patients participating in pulmonary 
rehabilitation. COPD. 2012;9:12–5.
 12. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connective 
tissue diseases. Clin Chest Med. 2008;29:149–64.
 13. Jones PW, Tabberer M, Chen W-H. Creating scenarios of the impact of COPD 
and their relationship to COPD assessment test (CATTM) scores. BMC Pulm 
Med. 2011;11:42.
 14. Hachulla E, Clerson P, Airo P, et al. Value of systolic pulmonary arterial pressure 
as a prognostic factor of death in the systemic sclerosis EUSTAR population. 
Rheumatology. 2015;54:1262–9.
 15. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary com-
plications and long-term survival in systemic sclerosis. Arthritis Rheum. 
2014;66:1625–35.
 16. Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Dose long-term oxygen 
therapy affect quality of life in patients with chronic obstructive pulmonary dis-
ease and severe hypoxaemia? Eur Respir J. 1996;9:2335–9.
 17. Berry CE, Drummond MB, Han MK, et al. Relationship between lung func-
tion impairment and health-related quality of life in COPD and interstitial lung 
disease. Chest. 2012;142:704–11.
 18. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences 
in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and 
chronic obstructive pulmonary disease. Respiration. 2011;81:196–205.
 19. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. 
Relationship between FEV1 change and patient-reported outcomes in random-
ized trials of inhaled bronchodilators for stable COPD: a systematic review. 
Respir Res. 2011;12:40.
 20. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related qual-
ity of life in patients with interstitial lung disease. Chest. 1999;116:1175–82.
 21. Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific intersti-
tial pneumonia: prognostic significance of cellular and fibrosing patterns: 
survival comparison with usual interstitial pneumonia and desquamative inter-
stitial pneumonia. Am J Surg Pathol. 2000;24:19–33.
 22. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial 
lung disease: connective tissue disease-associated interstitial lung disease: how 
does it differ from IPF? How should the clinical approach differ? Chron Respir 
Dis. 2011;8:53–82.
COPD assessment test as a prognostic marker in interstitial lung disease
31CliniCal MediCine insights: CirCulatory, respiratory and pulMonary MediCine 2016:10
SCORE
i never cough 0 1 2 3 4 5 i cough all the time
i have no phlegm (mucus) in my chest at all 0 1 2 3 4 5 My chest is completely full of phlegm (mucus)
My chest does not feel tight at all 0 1 2 3 4 5 My chest feels very tight
When I walk up a hill or one flight of stairs I am  
not breathless
0 1 2 3 4 5 When I walk up a hill or one flight of stairs I am  
very breathless
i am not limited doing any activities at home 0 1 2 3 4 5 i am very limited doing activities at home
I am confident leaving my home despite  
my lung condition
0 1 2 3 4 5 I am not at all confident leaving my home because  
of my lung condition
i sleep soundly 0 1 2 3 4 5 i don’t sleep soundly because of my lung condition
i have lots of energy 0 1 2 3 4 5 i have no energy at all
SCORE
this questionnaire was developed by Jones et al.9
Appendix
The COPD Assessment Test (CAT)
For each item below, place a mark (√) in the box that best describes your experience.
example: i am very happy 0 √1 2 3 4 5 i am very sad
